Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, when used as a second-line therapy for type 2 diabetes, helped reduce glycated hemoglobin (HbA1c) by at least 0.5% and weight by at least 2 kg in over one-third of patients in 18 months, according to a study published in BMC Medicine.

The researchers of this retrospective study analyzed the benefits of adding a second-line glucose-lowering therapy to metformin on HbA1c levels, weight reduction, and treatment persistence in adults with type 2 diabetes. Patients were grouped into arms on the basis of their second-line therapy: sulfonylurea (n=4655), dipeptidyl peptidase-4 (DPP-4) inhibitor (n=2899), sodium–glucose cotransporter 2 (SGLT-2) inhibitor (n=441), or all other therapies (n=1102). HbA1c levels and body weight were recorded at baseline and at 6, 12, and 18 months.

In regard to patients remaining on their baseline therapy, the SGLT-2 inhibitor group had the highest consistency rate, at 57.7%, and the all other therapy groups had the lowest consistency rate, at 47.2%. As a whole, patients who did not change or adjust their therapy had a change in HbA1c of -1.38% at 6 months, -1.32% at 12 months, and -1.20% at 18 months. The sulfonylurea and SGLT-2 inhibitor groups had significant reductions of HbA1c at 6 months (-1.33% and -1.26%, respectively; P <.001), and the SGLT-2 inhibitor group had the greatest reductions at 18 months (-1.46%). Over the 18-month period, patients in the SGLT-2 inhibitor group and the DPP-4 inhibitor group had significant reductions in mean weight (-4.2 kg and -1.5 kg respectively; P <.001). Overall, the SGLT-2 inhibitor group had the greatest treatment success, with 36.5% of patients continuing on treatment, reducing HbA1c by at least 0.5%, and reducing weight by at least 2 kg. DPP-4 inhibitors had a success rate of 17.1%, sulfonylurea had a success rate of 9.6%, and all other therapies had a success rate of 9.1%.

Continue Reading

Related Articles

Some limitations of this study were the reduction of patients due to changing therapies from baseline to 18 months and the limited number of patients on DPP-4 and SGLT-2 inhibitors (because these are newer forms of treatment and not widely used at the time of data collection). Future studies need to expand on these results by analyzing other first-line treatments with these second-line therapies. 

In conclusion, all groups of this study had reductions in HbA1c levels, with patients adding SGLT-2 inhibitors having the greatest reduction. SGLT-2 inhibitors also had the highest treatment success rate, which could make this family of therapies a viable option for patients.

This study was supported by AstraZeneca. Please refer to reference for a complete list of authors’ disclosures.


Wilding J, Godec T, Khunti K, et al. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Med. 2018;16(1):116.